申请人:Novo Nordisk A/S
公开号:US05532236A1
公开(公告)日:1996-07-02
The present invention relates to [1,2,4]triazolo[4,3-a quinoxaline derivatives of formula I ##STR1## wherein one of R.sup.1 and R.sup.2 is a 5- or 6-membered nitrogen-containing heterocyclic ring which is optionally substituted with one, two or three substituents, wherein each substituent is independently phenyl or C.sub.1-6 -alkyl, or one of R.sup.1 and R.sup.2 is a fused ring system comprising a 5- or 6-membered nitrogen-containing heterocyclic ring and a benzene, pyridine, pyrimidine or pyrazine ring, wherein the fused ring system is optionally substituted with phenyl or C.sub.1-6 -alkyl; and the other of R.sup.1 and R.sup.2 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy, halogen, NO.sub.2, NH.sub.2, CN, CF.sub.3, COC.sub.1-6 -alkyl or SO.sub.2 NR'R", wherein R' and R" are independently hydrogen or C.sub.1-6 -alkyl; and X is O or S; and pharmaceutically acceptable salts thereof. The compounds have affinity for the AMPA receptors and are antagonists in connection with this type of receptors which makes them useful in the treatment of CNS ailments, especially in the treatment of any of the numerous indications caused by hyperactivity of excitatory amino acids.
本发明涉及式I的[1,2,4]三唑并[4,3-a]喹喔啉衍生物,其中R.sup.1和R.sup.2中的一个是5-或6-成员含氮杂环,可以选择性地用一个、两个或三个取代基取代,其中每个取代基独立地是苯基或C.sub.1-6-烷基,或者R.sup.1和R.sup.2中的一个是包括5-或6-成员含氮杂环和苯、吡啶、嘧啶或吡嗪环的融合环系统,其中融合环系统可以选择性地用苯基或C.sub.1-6-烷基取代;另一个是氢、C.sub.1-6-烷基、C.sub.1-6-烷氧基、卤素、NO.sub.2、NH.sub.2、CN、CF.sub.3、COC.sub.1-6-烷基或SO.sub.2NR'R"中的一个,其中R'和R"独立地是氢或C.sub.1-6-烷基;X是O或S;以及其药学上可接受的盐。这些化合物对AMPA受体具有亲和力,并且在与这种类型的受体有关的拮抗作用,使它们在治疗中枢神经系统疾病方面有用,特别是在治疗由兴奋性氨基酸过度活跃引起的众多症状的治疗中。